Arterial hypertension, cardiovascular remodeling and plasma level of osteopontin in patients with end-stage kidney disease on hemodialysis
DOI:
https://doi.org/10.14739/2310-1210.2014.6.35647Keywords:
End-Stage Renal Disease, Hemodialysis, Hypertension, Osteopontin, CandesartanAbstract
Aim. Large population-based studies acknowledge that patients with chronic kidney disease have a high risk of cardiovascular diseases regardless of etiology, especially in its late stages. The aim of this study was to investigate the features of arterial hypertension, cardiovascular remodeling and plasma level of osteopontin in dynamics of candesartan therapy, as well as to identify the relationships between studied parameters in patients with chronic kidney disease treated by hemodialysis.
Methods and results. 50 patients were performed ambulatory blood pressure monitoring, the plasma level of osteopontin was determined by ELISA method, standard echocardiography and ultrasonography of common carotid after treatment of candesartan during 12 weeks.
Conclusion. The results indicate that the use of candesartan cilexetil in hemodialysis populations promotes regression of left ventricular hypertrophy and vascular remodeling indices, has antihypertensive effect.
References
Vizir, V. A., & Berezin, A. E. (2010) Osteopontin kak novyj biologicheskij marker kardiovaskulyarnogo remodelirovaniya [Osteopontin as a new biological marker of cardiovascular remodeling]. Krovoobіh ta hemostaz, 1/2, 42–47. [in Ukrainian].
Garsia-Donaire, J. A. (2013) Kardio-vaskulyarno-renalnie svyazi v kardiorenalnom kontinuume [Cardio-vascular-renal connection in cardiorenal continuum]. Nefrologiya, 17(1), 11–19. [in Russian].
Rtischeva, O. V., & Kalev, O. F. (2011) Osobennosti strukturnogo remodelirovaniya miokarda u bolnikh arterial`noj gipertenziej, nahodyaschikhsya na gemodialize [Features of structural remodeling in hypertensive patients on hemodialysis]. Klinicheskaya nefrologiya, 2, 35–39. [in Russian].
Barra, S., Vitagliano, A., Cuomo, V., Vitagliano, G., & Gaeta, G. (2009) Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opin. Pharmacother, 10(2), 173–189. doi: 10.1517/14656560802653180 .
Cecilia, M. Giachelli. (2009) The emerging role of phosphate in vascular calcification. Кidney International, 75, 890–897. doi: 10.1038/ki.2008.644.
Denhardt, D. T., Noda, M., & O’Regan, A W. (2007) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest., 107, 1055–1061.
Devereux, R.,B., Alonso, D. R., & Lutas, E. M. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol., 57, 450–458. doi: 10.1016/0002-9149(86)90771-X
(2013) ESH/ESC Guidelines for the management of arterial hypertension.
Friedman, O., McAlister, F. A., Yun, L, Campbell, N. R, Tu (2010) Canadian hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am. J. Med., 123(2), 173–181.
Cecilia, M. Giachelli, Mei Y. Speer, Xianwu Li, Rupak M. Rajachar and Hsueh Yang (2005) Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res., 96, 717–722.
Glynn, L. G., Reddan, D., & Newell, J. (2007) Cronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland communiti-based cohort study. Nephrol Dial Transplant., 22(9), 2586–2594.
Grau, J. B, Poggio P, & Sainger, R. (2012) Osteopontin Levels for the Identification of Asymptomatic Patients with Calcific Aortic Valve Disease. Annals of Thoracic Surgery. Annals of Thoracic Surgery, 93(1), 79–86. doi: 10.1016/j.athoracsur.2011.08.036
Hatanaka, Y., Umekawa, T., Iguchi, M., & Kurita, T. (2005) Evaluation of the crystal inhibitory effect of angiotensin II type I receptor blocker in etylene glycol treated rat kidney. Nippon Hinyokika Gakkai Zasshi, 96(4), 487–494.
Heerspink, H. J., Ninomiya, T., Zoungas, S., De Zeeuw, D., Grobbee, D. E., & Jardine, M. J. (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet, 373, 1009–1015. doi: 10.1016/S0140-6736(09)60212-9.
Jula, K. Inrig (2010) Аntihypertensive Agents in Hemodialysis Patients: A Current Perspective. Semin Dial., 23(3), 290–297. doi: 10.1111/j.1525-139X.2009.00697.x.
Kurata, M., Okura, T., Irita, J., Enomoto, D., Nagao, T., & Jotoku M. (2011) Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J Hum Hypertens., 25(5), 334–339. doi: 10.1038/jhh.2010.73.
Lorenzen, J. M, Neunhöffer, H., David, S, Kielstein, J. T, Haller, H., & Fliser, D. (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial. Atherosclerosis, 209(1), 184–188. doi: 10.1016/j.atherosclerosis.2009.09.009
Lullo, L. D., Floccari, F., & Santoboni, A. (2013) Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol., 26(4), 739–744. doi: 10.5301/jn.5000290.
Nakayama, H., Nagai, H., Matsumoto, K., Oguro, R., Sugimoto, K., Kamide, K., Fujio, Y. (2011). Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population. Hypertension Research, 1141–1146. doi: 10.1038/hr.2011.102.
(2005) National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis. Am J Kidney Dis., 45, 1-1537.
Sakurabayashi-Kitade, S., Aoka, Y, Nagashima, H., Kasanuki, H., Hagiwara, N., & Kawana, M. (2009) Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling inangiotensin II overproducing transgenic mice. Atherosclerosis, 206(1), 54–60.
Takahashi, A., Takase, H, & Toriyama, T (2006) Candecartan, an angiotensin II type -1 receptor blocker, reduced cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant., 21(9), 2507–2512.
Uaesoontrachoon, K., Yoo, H., Tudor, E., Pike, R., Mackie, E., & Pagel, C. (n.d.). Osteopontin and skeletal muscle myoblasts: Association with muscle regeneration and regulation of myoblast function in vitro. The International Journal of Biochemistry & Cell Biology, 2303–2314. doi: 10.1016/j.biocel.2008.03.020.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
